A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

September 30, 2008

Conditions

Atopic Dermatitis

Interventions

DRUG

50 mg S-777469

S-777469, 50 mg BID

DRUG

200 mg S-777469

S-777469, 200 mg BID

DRUG

800 mg S-777469

S-777469, 800 mg BID

DRUG

Placebo

Matching Placebo

Trial Locations (1)

Comprehensive Phase One, Miramar